NephCure Kidney International and HEAL Collaborative Partner to Launch Health Equity Initiative
Initiative seeks to create interventions to prevent kidney failure and improve access to kidney disease research, care for communities of color
News provided by
Share this article
HEAL Collaborative logo
KING OF PRUSSIA, Pa., March 9, 2021 /PRNewswire/ Today, NephCure Kidney International (NephCure) announced the formal launch of its Health Equity Initiative, focused on addressing access to research and care for diverse families living with chronic, protein-spilling kidney diseases, together with the Health Education Advocacy and Learning, Inc. (HEAL Collaborative) not-for-profit organization.
The goal of this initiative is to improve patient outcomes by identifying solutions to strengthen the participation of underrepresented individuals in the kidney disease patient and medical arena. The initial focus will be on kidney disease in Black Americans, given the prevalence of Chroni
NephCure Kidney International and HEAL Collaborative Partner to Launch Health Equity Initiative
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
A call to action to address racial inequities in medical tests
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
EXTON, Pa., March 4, 2021 /PRNewswire/ Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic complications, hyperkalemia, and metabolic acidosis. At the American Society of Nephrology (ASN) fall 2020 conference, Kidney Week Reimagined, news about SGLT2 inhibitors for CKD patients with
and without diabetes created a stir and caused optimism about potential paradigm shifts for CKD patients.
The fierce competition between AstraZeneca and Vifor/Relypsa in the hyperkalemia market will likely spill into the SGLT2 inhibitor market in 2021, with potential additional complexities surrounding other in-class SGLT2 inhibitors (Eli Lilly/Boehringer Ingelheim s Jardiance and Pfizer/Merck s Steglatro), as well as the much-anticipated diabetic kidney disease (DKD) pipeline agent from Bayer, finerenone.
Assessing patients kidney health may help predict their risk of cardiovascular disease
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.